Previous research from our laboratory demonstrated that proTAME-containing therapies reduced CDC20 expression and increased the Bax/Bcl-2 ratio in RT4 cells, promoting apoptosis, while reducing this ratio in ARPE-19 cells, indicating a selective effect on cancer cells [23]. This evidence concerns the gene BCL2 and cancer.